Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Cancerous inhibitor of protein phosphatase 2A (CIP2A) modifies energy metabolism via 5' AMP-activated protein kinase signalling in malignant cells.

Austin JA, Jenkins RE, Austin GM, Glenn MA, Dunn K, Scott L, Lucas CM, Clark RE.

Biochem J. 2019 Aug 15;476(15):2255-2269. doi: 10.1042/BCJ20190121.

PMID:
31350330
2.

Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".

Perrotti D, Agarwal A, Lucas CM, Narla G, Neviani P, Odero MD, Ruvolo PP, Verrills NM.

Sci Transl Med. 2019 Jul 17;11(501). pii: eaau0416. doi: 10.1126/scitranslmed.aau0416.

PMID:
31316003
3.

A defined mechanistic correlate of protection against Plasmodium falciparum malaria in non-human primates.

Douglas AD, Baldeviano GC, Jin J, Miura K, Diouf A, Zenonos ZA, Ventocilla JA, Silk SE, Marshall JM, Alanine DGW, Wang C, Edwards NJ, Leiva KP, Gomez-Puerta LA, Lucas CM, Wright GJ, Long CA, Royal JM, Draper SJ.

Nat Commun. 2019 Apr 26;10(1):1953. doi: 10.1038/s41467-019-09894-4.

4.

Effectiveness of the European Society of Cardiology/Heart Failure Association website 'heartfailurematters.org' and an e-health adjusted care pathway in patients with stable heart failure: results of the 'e-Vita HF' randomized controlled trial.

Wagenaar KP, Broekhuizen BDL, Jaarsma T, Kok I, Mosterd A, Willems FF, Linssen GCM, Agema WRP, Anneveldt S, Lucas CMHB, Mannaerts HFJ, Wajon EMCJ, Dickstein K, Cramer MJ, Landman MAJ, Hoes AW, Rutten FH.

Eur J Heart Fail. 2019 Feb;21(2):238-246. doi: 10.1002/ejhf.1354. Epub 2018 Nov 28.

5.

Genetic Variability of Plasmodium vivax in the North Coast of Peru and the Ecuadorian Amazon Basin.

Ventocilla JA, Nuñez J, Tapia LL, Lucas CM, Manock SR, Lescano AG, Edgel KA, Graf PCF.

Am J Trop Med Hyg. 2018 Jul;99(1):27-32. doi: 10.4269/ajtmh.17-0498. Epub 2018 May 10.

6.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML.

Lucas CM, Scott LJ, Carmell N, Holcroft AK, Hills RK, Burnett AK, Clark RE.

Blood Adv. 2018 May 8;2(9):964-968. doi: 10.1182/bloodadvances.2017013615. No abstract available.

7.

The mechanisms of a mammalian splicing enhancer.

Jobbins AM, Reichenbach LF, Lucas CM, Hudson AJ, Burley GA, Eperon IC.

Nucleic Acids Res. 2018 Mar 16;46(5):2145-2158. doi: 10.1093/nar/gky056.

8.

Stiff left atrial syndrome as another cause for heart failure with preserved ejection fraction and normal BNP levels.

Lucas CM.

Neth Heart J. 2017 Mar;25(3):224. doi: 10.1007/s12471-016-0924-5. No abstract available.

9.

Population genomics studies identify signatures of global dispersal and drug resistance in Plasmodium vivax.

Hupalo DN, Luo Z, Melnikov A, Sutton PL, Rogov P, Escalante A, Vallejo AF, Herrera S, Arévalo-Herrera M, Fan Q, Wang Y, Cui L, Lucas CM, Durand S, Sanchez JF, Baldeviano GC, Lescano AG, Laman M, Barnadas C, Barry A, Mueller I, Kazura JW, Eapen A, Kanagaraj D, Valecha N, Ferreira MU, Roobsoong W, Nguitragool W, Sattabonkot J, Gamboa D, Kosek M, Vinetz JM, González-Cerón L, Birren BW, Neafsey DE, Carlton JM.

Nat Genet. 2016 Aug;48(8):953-8. doi: 10.1038/ng.3588. Epub 2016 Jun 27.

10.

How livestock and flooding mediate the ecological integrity of working forests in Amazon River floodplains.

Lucas CM, Sheikh P, Gagnon PR, Mcgrath DG.

Ecol Appl. 2016 Jan;26(1):190-202.

PMID:
27039519
11.

High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia.

Lucas CM, Milani M, Butterworth M, Carmell N, Scott LJ, Clark RE, Cohen GM, Varadarajan S.

Leukemia. 2016 Jun;30(6):1273-81. doi: 10.1038/leu.2016.42. Epub 2016 Feb 29.

12.

Outbreak of Cutaneous Leishmaniasis in Peruvian Military Personnel Undertaking Training Activities in the Amazon Basin, 2010.

Oré M, Sáenz E, Cabrera R, Sanchez JF, De Los Santos MB, Lucas CM, Núñez JH, Edgel KA, Sopan J, Fernández J, Carnero AM, Baldeviano GC, Arrasco JC, Graf PCF, Lescano AG.

Am J Trop Med Hyg. 2015 Aug;93(2):340-346. doi: 10.4269/ajtmh.15-0107. Epub 2015 Jun 15.

13.

Heart failure in 2015: let's get organised!

Lucas CM, van Pol PE, Eysink Smeets JB, Niesing M, Verwey HF, Beeres SL.

Neth Heart J. 2015 Aug;23(9):447-9. doi: 10.1007/s12471-015-0722-5. No abstract available.

14.

Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.

Lucas CM, Harris RJ, Holcroft AK, Scott LJ, Carmell N, McDonald E, Polydoros F, Clark RE.

Leukemia. 2015 Jul;29(7):1514-23. doi: 10.1038/leu.2015.71. Epub 2015 Mar 13.

PMID:
25765543
15.

c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia.

Lucas CM, Harris RJ, Giannoudis A, Clark RE.

Haematologica. 2015 May;100(5):e179-82. doi: 10.3324/haematol.2014.115691. Epub 2015 Feb 6. No abstract available.

16.

A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys.

Douglas AD, Baldeviano GC, Lucas CM, Lugo-Roman LA, Crosnier C, Bartholdson SJ, Diouf A, Miura K, Lambert LE, Ventocilla JA, Leiva KP, Milne KH, Illingworth JJ, Spencer AJ, Hjerrild KA, Alanine DG, Turner AV, Moorhead JT, Edgel KA, Wu Y, Long CA, Wright GJ, Lescano AG, Draper SJ.

Cell Host Microbe. 2015 Jan 14;17(1):130-9. doi: 10.1016/j.chom.2014.11.017.

17.

A targeted oligonucleotide enhancer of SMN2 exon 7 splicing forms competing quadruplex and protein complexes in functional conditions.

Smith LD, Dickinson RL, Lucas CM, Cousins A, Malygin AA, Weldon C, Perrett AJ, Bottrill AR, Searle MS, Burley GA, Eperon IC.

Cell Rep. 2014 Oct 9;9(1):193-205. doi: 10.1016/j.celrep.2014.08.051. Epub 2014 Sep 25.

18.

Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia.

Lucas CM, Harris RJ, Giannoudis A, McDonald E, Clark RE.

Haematologica. 2014 Nov;99(11):1710-5. doi: 10.3324/haematol.2013.101972. Epub 2014 Sep 5.

19.

The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia.

Giannoudis A, Davies A, Harris RJ, Lucas CM, Pirmohamed M, Clark RE.

Leukemia. 2014 Jun;28(6):1360-3. doi: 10.1038/leu.2014.38. Epub 2014 Jan 20. No abstract available.

PMID:
24441286
20.

Intron retention in the alternatively spliced region of RON results from weak 3' splice site recognition.

Smith LD, Lucas CM, Eperon IC.

PLoS One. 2013 Oct 14;8(10):e77208. doi: 10.1371/journal.pone.0077208. eCollection 2013.

21.

Exercise-resembling effects of periodic somatosensory stimulation in heart failure.

Gademan MG, van Exel HJ, van de Vooren H, Haest JC, van Pelt J, van der Laarse A, Cannegieter SC, Lucas CM, Somer S, Verwey HF, Schalij MJ, van der Wall EE, Swenne CA.

Int J Cardiol. 2013 Oct 9;168(4):3327-33. doi: 10.1016/j.ijcard.2013.04.040. Epub 2013 May 3.

PMID:
23643425
22.

A FRET-based real-time PCR assay to identify the main causal agents of New World tegumentary leishmaniasis.

Tsukayama P, Núñez JH, De Los Santos M, Soberón V, Lucas CM, Matlashewski G, Llanos-Cuentas A, Ore M, Baldeviano GC, Edgel KA, Lescano AG, Graf PC, Bacon DJ.

PLoS Negl Trop Dis. 2013;7(1):e1956. doi: 10.1371/journal.pntd.0001956. Epub 2013 Jan 3.

23.

Natural Leishmania infection of Lutzomyia auraensis in Madre de Dios, Peru, detected by a fluorescence resonance energy transfer-based real-time polymerase chain reaction.

Valdivia HO, De Los Santos MB, Fernandez R, Baldeviano GC, Zorrilla VO, Vera H, Lucas CM, Edgel KA, Lescano AG, Mundal KD, Graf PC.

Am J Trop Med Hyg. 2012 Sep;87(3):511-7. doi: 10.4269/ajtmh.2012.11-0708. Epub 2012 Jul 16.

24.

Rapid diagnosis of chronic myeloid leukemia by flow cytometric detection of BCR-ABL1 protein.

Lucas CM, Fagan JL, Carter A, Swale B, Evans C, Clark RE, Harris RJ.

Haematologica. 2011 Jul;96(7):1077-8. doi: 10.3324/haematol.2011.043166. Epub 2011 May 5. No abstract available.

25.

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression.

Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE.

Blood. 2011 Jun 16;117(24):6660-8. doi: 10.1182/blood-2010-08-304477. Epub 2011 Apr 13.

PMID:
21490338
26.

Rehabilitation: Periodic somatosensory stimulation increases arterial baroreflex sensitivity in chronic heart failure patients.

Gademan MG, Sun Y, Han L, Valk VJ, Schalij MJ, van Exel HJ, Lucas CM, Maan AC, Verwey HF, van de Vooren H, Pinna GD, Maestri R, La Rovere MT, van der Wall EE, Swenne CA.

Int J Cardiol. 2011 Oct 20;152(2):237-41. doi: 10.1016/j.ijcard.2010.07.022. Epub 2010 Aug 9.

PMID:
20691484
27.

BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia.

Lucas CM, Harris RJ, Giannoudis A, Knight K, Watmough SJ, Clark RE.

Br J Haematol. 2010 May;149(3):458-60. doi: 10.1111/j.1365-2141.2009.08066.x. Epub 2010 Jan 11. No abstract available.

PMID:
20067558
28.

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.

Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, Wang L, Clark RE.

Haematologica. 2009 Oct;94(10):1362-7. doi: 10.3324/haematol.2009.009134. Epub 2009 Aug 27.

29.

Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.

Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ, Jørgensen HG, Holyoake TL, Pirmohamed M, Clark RE, Mountford JC.

Leukemia. 2009 Nov;23(11):1999-2006. doi: 10.1038/leu.2009.166. Epub 2009 Aug 27.

PMID:
19710702
30.

A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials.

Lucas CM, Wang L, Austin GM, Knight K, Watmough SJ, Shwe KH, Dasgupta R, Butt NM, Galvani D, Hoyle CF, Seale JR, Clark RE.

Leukemia. 2008 Oct;22(10):1963-6. doi: 10.1038/leu.2008.225. Epub 2008 Aug 28. No abstract available.

PMID:
18754023
31.

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia.

Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE.

Blood. 2008 Oct 15;112(8):3348-54. doi: 10.1182/blood-2007-10-116236. Epub 2008 Jul 31.

32.

Genetic diversity of vaccine candidate antigens in Plasmodium falciparum isolates from the Amazon basin of Peru.

Chenet SM, Branch OH, Escalante AA, Lucas CM, Bacon DJ.

Malar J. 2008 May 27;7:93. doi: 10.1186/1475-2875-7-93.

33.

Exercise training increases oxygen uptake efficiency slope in chronic heart failure.

Gademan MG, Swenne CA, Verwey HF, van de Vooren H, Haest JC, van Exel HJ, Lucas CM, Cleuren GV, Schalij MJ, van der Wall EE.

Eur J Cardiovasc Prev Rehabil. 2008 Apr;15(2):140-4. doi: 10.1097/HJR.0b013e3282ef19986.

PMID:
18391638
34.

Anemia and antibodies to the 19-kDa fragment of MSP1 during Plasmodium falciparum infection in Aotus monkeys.

Gozalo AS, Lucas CM, Qin J, Hall BT, Magill AJ.

Comp Med. 2007 Aug;57(4):396-401.

PMID:
17803055
35.

Effect of exercise training on autonomic derangement and neurohumoral activation in chronic heart failure.

Gademan MG, Swenne CA, Verwey HF, van der Laarse A, Maan AC, van de Vooren H, van Pelt J, van Exel HJ, Lucas CM, Cleuren GV, Somer S, Schalij MJ, van der Wall EE.

J Card Fail. 2007 May;13(4):294-303. Review.

PMID:
17517350
36.
37.

Practical implications of having a dedicated heart failure programme.

Lucas CM, Cleuren GV, Jaarsma T, van Rees C, Kirchhof CJ.

Neth Heart J. 2005 Oct;13(10):343-347.

38.

Measuring quality of life in heart failure: one versus multiple items.

Jaarsma T, Lesman-Leegte GA, Cleuren GV, Lucas CM.

Neth Heart J. 2005 Oct;13(10):338-342.

39.
40.

Multidisciplinary heart failure programmes: where do we stand in the Netherlands?

Lucas CM.

Neth Heart J. 2005 Feb;13(2):45-46. No abstract available.

41.
42.

Geographic distribution and clinical description of leishmaniasis cases in Peru.

Lucas CM, Franke ED, Cachay MI, Tejada A, Cruz ME, Kreutzer RD, Barker DC, McCann SH, Watts DM.

Am J Trop Med Hyg. 1998 Aug;59(2):312-7.

PMID:
9715953
43.

Structural alterations in the latissimus dorsi muscles in three patients more than 2 years after a cardiomyoplasty procedure.

Davidse JH, van der Veen FH, Lucas CM, Penn OC, Daemen MJ, Wellens HJ.

Eur Heart J. 1998 Feb;19(2):310-8.

PMID:
9519326
44.

Metabolic flux response to salt-induced stress in the halotolerant yeast Debaryomyces hansenii.

Neves ML, Oliveira RP, Lucas CM.

Microbiology. 1997 Apr;143 ( Pt 4):1133-9.

PMID:
9141676
45.

Creating a practice partnership: a clinical application of case management.

Lucas CM, Dierks EJ, Parker N.

Adv Pract Nurs Q. 1995 Fall;1(2):49-63.

PMID:
9447015
46.

Leishmania (Viannia) lainsoni: first isolation in Peru.

Lucas CM, Franke ED, Cachay MI, Tejada A, Carrizales D, Kreutzer RD.

Am J Trop Med Hyg. 1994 Nov;51(5):533-7.

PMID:
7985744
47.

Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis.

Franke ED, Llanos-Cuentas A, Echevarria J, Cruz ME, Campos P, Tovar AA, Lucas CM, Berman JD.

Am J Trop Med Hyg. 1994 Jul;51(1):77-82.

PMID:
8059918
48.

A new stimulation protocol for cardiac assist using the latissimus dorsi muscle.

Lucas CM, Dubelaar ML, Van der Veen FH, Kloosterman-Castro-Ravelo E, Havenith M, Habets J, Van der Nagel T, Penn OC, Wellens HJ.

Pacing Clin Electrophysiol. 1993 Oct;16(10):2012-21.

PMID:
7694248
49.

Long-term follow-up (12 to 35 weeks) after dynamic cardiomyoplasty.

Lucas CM, Van der Veen FH, Cheriex EC, Lorusso R, Havenith M, Penn OC, Wellens HJ.

J Am Coll Cardiol. 1993 Sep;22(3):758-67.

50.

The importance of muscle relaxation in dynamic cardiomyoplasty.

Lucas CM, van der Veen FH, Cheriex EC, van Ommen V, Penn OC, Wellens HJ.

Pacing Clin Electrophysiol. 1992 Oct;15(10 Pt 1):1430-6.

PMID:
1383953

Supplemental Content

Loading ...
Support Center